Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. develops investigational biologics intended to enhance regulatory T-cell, or Treg, function in neurodegenerative disorders. Company news centers on COYA 302, including clinical and regulatory updates in amyotrophic lateral sclerosis and frontotemporal dementia, biomarker publications, and research on systemic inflammation, lipid peroxidation, axonal injury, and Treg dysfunction.
Coya updates also cover its Treg-focused therapeutic platforms, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Recurring business developments include collaboration activity with Dr. Reddy’s Laboratories, milestone-related revenue disclosures, operating results, stockholder communications, and board or governance changes.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in two upcoming conferences in May 2025. The company's leadership, including CEO Dr. Arun Swaminathan and CFO David Snyder, will be available for one-on-one meetings with registered investors at:
1. The D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York
2. The Mizuho Neuro & Opthalmology Summit from May 20-21, 2025, at the Park Lane Hotel in New York
Coya Therapeutics (NASDAQ: COYA) has announced positive interim results from an investigator-initiated open-label study testing low-dose IL-2 and CTLA4-Ig combination treatment in Frontotemporal Dementia (FTD) patients. The study, conducted at Houston Methodist Neurological Institute, showed promising results in the first cohort of 5 patients.
Key findings include:
- Statistically significant increase in Treg numbers and suppressive function
- Minimal to no cognitive decline throughout the study period
- Well-tolerated treatment with no serious adverse events
- All 5 patients completed the 22-week treatment course
This is particularly notable as FTD patients typically experience rapid cognitive decline, with historical data showing an average 3.57-point worsening over 12 months on the CDR-FTLD scale. The treatment's success in maintaining cognitive function suggests potential therapeutic value for FTD, which currently has no approved treatments.
Coya Therapeutics (NASDAQ: COYA) has published research results for COYA 303, a novel biologic combination of low-dose interleukin 2 (LD IL-2) and GLP-1 receptor agonist (GLP-1RA), designed to enhance regulatory T cell (Treg) function in autoimmune and neurodegenerative diseases.
The study, conducted at Houston Methodist Research Institute, demonstrated that COYA 303 achieved a 42% increase in Treg suppressive function, significantly outperforming individual components (LD IL-2 at 15% and GLP-1RA at 20%). The combination therapy also showed enhanced Treg survival through reduced BAX transcript levels and inhibition of Treg apoptosis.
The research suggests COYA 303 could offer a differentiated approach for conditions like Alzheimer's Disease, where GLP-1 RAs have shown promise, by combining anti-inflammatory effects with enhanced Treg survival and function.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company focused on regulatory T cell (Treg) function enhancement, has announced an upcoming presentation at the ADPD 2025 conference in Vienna.
Principal Investigator Dr. Alireza Faridar from Houston Methodist Hospital will present progress updates on a Phase II clinical trial investigating low-dose IL-2 treatment in patients with mild to moderate Alzheimer's disease. The presentation is scheduled for April 5, 2025.
Coya Therapeutics (NASDAQ: COYA) provided an update on its Treg-derived exosome platform development for treating systemic and neurodegenerative diseases. The company's research has shown that regulatory T cell-derived exosomes (Treg exosomes) effectively suppress inflammation in preclinical models.
Key developments include:
- Treg exosomes demonstrated strong therapeutic potential in suppressing inflammation in neurodegenerative disease models
- Initial engineering batches using healthy donor Tregs planned for Q1 2025
- GMP manufacturing of larger-scale clinical batches scheduled for Q4 2025
- Program funded by Johnson Center for Cellular Therapeutics, Hop On A Cure, and Energy Transfer
The company highlighted that Treg exosomes have advantages over Tregs as they target myeloid cells driving disease progression and resist conversion to non-suppressive phenotypes in inflammatory environments.
Coya Therapeutics (NASDAQ: COYA) has reported its fiscal 2024 results and corporate updates. The company ended 2024 with $38.3 million in cash and reported a net loss of $14.9 million, compared to $8.0 million in 2023.
Key financial achievements include raising $10.0M through private placement, receiving a $5.0M strategic investment from the Alzheimer's Drug Discovery Foundation, and securing $3.85M from Dr. Reddy's Laboratories.
R&D expenses increased to $11.9 million in 2024 from $5.5 million in 2023, while G&A expenses rose to $8.9 million from $7.8 million.
The company announced positive results from Phase 2 studies in Alzheimer's disease and progress in Frontotemporal Dementia trials. Key upcoming catalysts for 2025 include submission of COYA-302 Phase 2 trial data for ALS treatment, potential milestone payments of $8.4M, and various data publications across their pipeline.
Coya Therapeutics (NASDAQ: COYA) announced that CEO Arun Swaminathan and Dr. Stanley H. Appel will participate in a BTIG-hosted KOL webcast titled "Is Alzheimer's next for GLP-1s and Combos?" on February 27, 2025. The discussion, moderated by Juliette Lafille of BTIG, will explore the potential of GLP-1 agonists and combination therapies for treating Alzheimer's disease.
Key topics will include:
- Potential for GLP-1s to slow cognitive decline in Alzheimer's
- Effects on brain metabolism and neuroinflammation reduction
- Efficacy through combinations
- Future development pathways
Coya recently expanded its pipeline with COYA 303, an investigational biologic combining COYA 301 (proprietary low-dose interleukin-2) with a GLP-1 receptor agonist designed for subcutaneous administration to treat inflammatory diseases.
Coya Therapeutics (NASDAQ: COYA) reported positive results from a Phase 2 study of low-dose IL-2 (LD IL-2) in Alzheimer's disease patients. The 21-week, double-blind, placebo-controlled trial demonstrated statistically significant improvements in inflammatory blood markers with monthly dosing.
Key findings include reduced levels of proinflammatory markers CCL2 (p0.05) and IL-15 (p<0.001), increased anti-inflammatory cytokine IL-4 (p<0.01), and improved beta amyloid 42 clearance. Patients receiving monthly LD IL-2 showed a 4.93-point improvement in ADAS-Cog score compared to placebo.The study involved 38 participants aged 50-86 with Alzheimer's disease. Monthly dosing proved more effective than biweekly administration. The treatment was well-tolerated with no serious adverse events reported. The comprehensive data set will be presented throughout 2025.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The conference will be held virtually from February 11-12, 2025. CEO Arun Swaminathan, Ph.D., will deliver a presentation on Tuesday, February 11, 2025, from 10:00 to 10:30 AM ET in Track 3. The presentation will be accessible via webcast, with the recording remaining available for one year on Coya's website under the 'Events and Presentations' section.
Company management will also be conducting one-on-one meetings with registered conference investors on February 11, 2025.
Coya Therapeutics (NASDAQ: COYA) has announced the expansion of its pipeline with COYA 303, a combination therapy of COYA 301 and GLP-1 receptor agonist for treating inflammatory diseases. COYA 303 is designed for subcutaneous administration and has shown promising results in preclinical studies with a dual immunomodulatory mechanism of action.
The company plans to publish the preclinical study results in a peer-reviewed publication in first half of 2025. The study demonstrated an additive/synergistic anti-inflammatory effect through increased Treg function and suppressed pro-inflammatory myeloid cells. Coya has filed several patent applications for the compound and is initiating translational studies with a major academic university.
The company aims to advance COYA 303 through IND-enabling studies alongside a strategic partner, focusing on neurodegenerative and autoimmune diseases.